LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Search

Danaher Corp

Suletud

SektorTervishoid

171.94 -0.71

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

171.1

Max

172.05

Põhinäitajad

By Trading Economics

Sissetulek

-168M

1B

Müük

-887M

6B

P/E

Sektori keskmine

31.756

49.701

Aktsiakasum

2.06

Dividenditootlus

0.84

Kasumimarginaal

17.291

Töötajad

58,000

EBITDA

-514M

1.5B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+34.67% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.84%

2.39%

Järgmine tulemuste avaldamine

21. juuli 2026

Järgmine dividendimakse kuupäev

31. juuli 2026

Järgmine aktsia dividendi kuupäev (ex-date)

26. juuni 2026

Turustatistika

By TradingEconomics

Turukapital

-22B

116B

Eelmine avamishind

172.65

Eelmine sulgemishind

171.94

Uudiste sentiment

By Acuity

56%

44%

283 / 345 Pingereas Healthcare

Danaher Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

21. apr 2026, 11:36 UTC

Tulu

Danaher Lifts Full-Year Forecast on Biotech, Life Sciences Gains -- Update

21. apr 2026, 11:00 UTC

Tulu

Danaher Raises Adjusted Earnings Guidance, 1Q Revenue, Profit Rise

21. apr 2026, 10:06 UTC

Tulu

Danaher 1Q Adjsuted Core Revenue Rose 0.5% >DHR

21. apr 2026, 10:05 UTC

Tulu

Danaher Sees 2Q Adjsuted Core Revenue Up Low-Single Digits >DHR

21. apr 2026, 10:05 UTC

Tulu

Danaher Still Sees 2026 Adjsuted Core Revenue Up 3%-6% >DHR

21. apr 2026, 10:05 UTC

Tulu

Danaher Had Seen 2026 Adjusted EPS $8.35-$8.50 >DHR

21. apr 2026, 10:04 UTC

Tulu

Danaher Raises 2026 View To Adj EPS $8.35-Adj EPS $8.55 >DHR

21. apr 2026, 10:04 UTC

Tulu

Danaher 1Q Operating Cash Flow $1.3B, Adjusted Free Cash Flow $1.1B >DHR

21. apr 2026, 10:00 UTC

Tulu

Danaher 1Q Cont Ops EPS $1.45 >DHR

21. apr 2026, 10:00 UTC

Tulu

Danaher 1Q Adj EPS $2.06 >DHR

21. apr 2026, 10:00 UTC

Tulu

Danaher 1Q Sales $5.95B >DHR

21. apr 2026, 10:00 UTC

Tulu

Danaher 1Q EPS $1.45 >DHR

21. apr 2026, 10:00 UTC

Tulu

Danaher 1Q Net $1.03B >DHR

17. apr 2026, 19:15 UTC

Market Talk

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17. apr 2026, 19:07 UTC

Market Talk

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17. veebr 2026, 20:06 UTC

Omandamised, ülevõtmised, äriostud

This Medical-Devices Stock Is Soaring. Danaher Is Buying the Company. -- Barrons.com

17. veebr 2026, 15:14 UTC

Omandamised, ülevõtmised, äriostud

Masimo Stock on Pace for Record Gains After Danaher Strikes Deal -- WSJ

17. veebr 2026, 14:39 UTC

Omandamised, ülevõtmised, äriostud

This Medical-Devices Stock Is Soaring. It's Being Bought by Danaher. -- Barrons.com

17. veebr 2026, 13:30 UTC

Omandamised, ülevõtmised, äriostud

This Medical-Devices Stock Is Soaring. It's Being Bought by Danaher. -- Barrons.com

17. veebr 2026, 13:15 UTC

Omandamised, ülevõtmised, äriostud

Danaher Strikes $10 Billion Deal for Masimo -- Update

17. veebr 2026, 13:03 UTC

Omandamised, ülevõtmised, äriostud

Danaher To Fund Masimo Acquisition With Cash on Hand, Debt Financing >DHR

17. veebr 2026, 13:03 UTC

Omandamised, ülevõtmised, äriostud

Danaher Sees More Than $125M Annual Cost Synergies, More Than $50M Annual Revenue Synergies by Fifth Full Year >DHR MASI

17. veebr 2026, 13:02 UTC

Omandamised, ülevõtmised, äriostud

Danaher Sees Masimo Deal Adding About 70c to Adjusted EPS in Fifth Full Year >DHR MASI

17. veebr 2026, 13:02 UTC

Omandamised, ülevõtmised, äriostud

Danaher Sees Masimo Deal Adding 15c-20c to Adjusted EPS in First Full Year >DHR MASI

17. veebr 2026, 13:02 UTC

Omandamised, ülevõtmised, äriostud

Masimo To Be Acquired By Danaher For $180.00 Per Share >MASI DHR

17. veebr 2026, 13:01 UTC

Omandamised, ülevõtmised, äriostud

Danaher to Buy Masimo for Total Enterprise Value of About $9.9 Billion >DHR MASI

17. veebr 2026, 13:00 UTC

Omandamised, ülevõtmised, äriostud

Danaher to Buy Masimo for $180/Share >DHR MASI

17. veebr 2026, 13:00 UTC

Omandamised, ülevõtmised, äriostud

Danaher To Acquire Masimo Corporation >DHR MASI

17. veebr 2026, 11:09 UTC

Omandamised, ülevõtmised, äriostud

Danaher Strikes $10 Billion Deal for Masimo -- WSJ

17. veebr 2026, 11:09 UTC

Omandamised, ülevõtmised, äriostud

Danaher Acquisition of Masimo Set to Be Announced Tuesday, Sources Say -- WSJ

Võrdlus sarnastega

Hinnamuutus

Danaher Corp Prognoos

Hinnasiht

By TipRanks

34.67% tõus

12 kuu keskmine prognoos

Keskmine 231.63 USD  34.67%

Kõrge 270 USD

Madal 184.04 USD

Põhineb 17 Wall Streeti analüütiku instrumendi Danaher Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

17 ratings

15

Osta

2

Hoia

0

Müü

Sentiment

By Acuity

283 / 345 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
help-icon Live chat